SATB1 protein is associated with the epithelial‑mesenchymal transition process in non‑small cell lung cancers.
EMT
LSCC
NSCLC
SATB1
adenocarcinoma
epithelial‑mesenchymal transition
lung adenocarcinoma
lung squamous cell carcinoma
metastasis
non‑small cell lung carcinoma
special AT‑rich binding protein 1
Journal
Oncology reports
ISSN: 1791-2431
Titre abrégé: Oncol Rep
Pays: Greece
ID NLM: 9422756
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
09
12
2020
accepted:
25
02
2021
entrez:
6
5
2021
pubmed:
7
5
2021
medline:
23
11
2021
Statut:
ppublish
Résumé
Lung cancer is one of the most frequently diagnosed neoplasms and the leading cause of cancer‑related mortality worldwide. Its predominant subtype is non‑small cell lung cancer (NSCLC), which accounts for over 80% of the cases. Surprisingly, the majority of lung cancer‑related deaths are caused not by a primary tumour itself, but by its metastasis to distant organs. Therefore, it becomes especially important to identify the factors involved in lung cancer metastatic spread. Special AT‑rich binding protein 1 (SATB1) is a nuclear matrix protein that mediates chromatin looping and plays the role of global transcriptional regulator. During the past decade, it has received much attention as a factor promoting tumour invasion. In breast, colorectal and prostate cancers, SATB1 has been shown to influence the epithelial‑mesenchymal transition (EMT) process, which is thought to be crucial for cancer metastasis. The aim of this study was to analyse the possible correlations between the expression of SATB1 and major EMT‑associated proteins in NSCLC clinical samples. Additionally, the impact of EMT induction in NSCLC cell lines on
Identifiants
pubmed: 33955522
doi: 10.3892/or.2021.8069
pii: 118
pmc: PMC8107643
doi:
pii:
Substances chimiques
Matrix Attachment Region Binding Proteins
0
SATB1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Mol Cell. 2006 Apr 21;22(2):231-43
pubmed: 16630892
Nat Rev Cancer. 2002 Jun;2(6):442-54
pubmed: 12189386
J Thorac Oncol. 2011 Jul;6(7):1179-89
pubmed: 21597389
Cancer Genomics Proteomics. 2016 May-Jun;13(3):209-17
pubmed: 27107063
Eur J Clin Invest. 2018 Apr;48(4):
pubmed: 29405291
Biochim Biophys Acta Rev Cancer. 2019 Jan;1871(1):29-39
pubmed: 30419315
Mol Biol Rep. 2012 Oct;39(10):9621-8
pubmed: 22729914
Oncotarget. 2018 Jun 12;9(45):27708-27727
pubmed: 29963231
Cancer Biol Ther. 2016;17(3):254-61
pubmed: 26810818
Mol Med Rep. 2015 May;11(5):3235-542
pubmed: 25586771
Methods. 2012 Nov;58(3):243-54
pubmed: 22782115
J Ovarian Res. 2012 Sep 19;5(1):24
pubmed: 22992394
Genes Dev. 2000 Mar 1;14(5):521-35
pubmed: 10716941
Clin Cancer Res. 2009 Nov 15;15(22):6820-9
pubmed: 19887480
PLoS One. 2012;7(1):e29954
pubmed: 22272264
J Egypt Natl Canc Inst. 2015 Sep;27(3):129-37
pubmed: 25964055
J Clin Med. 2019 May 14;8(5):
pubmed: 31091749
PLoS One. 2013;8(1):e53527
pubmed: 23308245
Front Oncol. 2019 Oct 11;9:1044
pubmed: 31681582
Anticancer Res. 2013 Nov;33(11):5091-5
pubmed: 24222154
Histol Histopathol. 2007 May;22(5):483-95
pubmed: 17330803
BMC Cancer. 2018 Oct 1;18(1):939
pubmed: 30285678
Front Med. 2018 Aug;12(4):361-373
pubmed: 30043221
Carcinogenesis. 2013 Aug;34(8):1889-99
pubmed: 23542418
Oncotarget. 2016 Jan 26;7(4):4993-5006
pubmed: 26701851
Trends Cell Biol. 2019 Mar;29(3):212-226
pubmed: 30594349
Crit Rev Oncol Hematol. 2013 Jul;87(1):1-11
pubmed: 23332547
Cancer Res. 2008 May 15;68(10):3645-54
pubmed: 18483246
PLoS One. 2013 Apr 23;8(4):e62171
pubmed: 23626784
Rom J Morphol Embryol. 2017;58(4):1317-1325
pubmed: 29556623
Cell Death Differ. 2011 Jan;18(1):16-25
pubmed: 20798686
Int J Cancer. 2014 Dec 1;135(11):2537-46
pubmed: 24729451
Mol Cell Biol. 2009 Mar;29(5):1321-37
pubmed: 19103759
Carcinogenesis. 2011 Sep;32(9):1299-304
pubmed: 21665887
Cancer Cell Int. 2013 Feb 05;13(1):8
pubmed: 23379909
Oncotarget. 2013 Dec;4(12):2512-22
pubmed: 24318272
BMC Med Genomics. 2014 Dec 11;7:68
pubmed: 25496125
J Cell Biol. 1991 Apr;113(1):173-85
pubmed: 2007622
Int J Clin Exp Pathol. 2014 Aug 15;7(9):5846-54
pubmed: 25337226
Nature. 2008 Mar 13;452(7184):187-93
pubmed: 18337816
Cell Death Dis. 2015 Jul 16;6:e1824
pubmed: 26181204
Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a003129
pubmed: 20457567
Diagn Pathol. 2012 Aug 30;7:115
pubmed: 22935204
Oncotarget. 2017 Jul 6;8(35):59950-59964
pubmed: 28938696
Curr Opin Genet Dev. 2007 Oct;17(5):408-14
pubmed: 17913490
Biol Rev Camb Philos Soc. 2018 Nov;93(4):1735-1746
pubmed: 29671943
Clin Cancer Res. 2000 Dec;6(12):4789-96
pubmed: 11156236
J Clin Oncol. 2002 May 15;20(10):2417-28
pubmed: 12011119
J Transl Med. 2013 May 04;11:111
pubmed: 23642278
Semin Cancer Biol. 2013 Apr;23(2):72-9
pubmed: 22771615
Oncol Lett. 2016 Nov;12(5):3818-3824
pubmed: 27895736
Front Biosci (Landmark Ed). 2009 Jan 01;14:3035-50
pubmed: 19273255
Respir Res. 2012 Nov 17;13:104
pubmed: 23157169
PLoS One. 2013;8(1):e47902
pubmed: 23326301
Curr Oncol. 2017 Aug;24(4):228-233
pubmed: 28874890
Clin Lung Cancer. 2012 Jul;13(4):280-7
pubmed: 22178381
Cancer Res Treat. 2004 Feb;36(1):56-61
pubmed: 20396566
Curr Biol. 2009 Sep 15;19(17):R762-71
pubmed: 19906578
Oncol Lett. 2017 Apr;13(4):2577-2582
pubmed: 28454436
Anticancer Res. 2018 Feb;38(2):723-736
pubmed: 29374696
Mol Clin Oncol. 2015 Jan;3(1):217-221
pubmed: 25469298
Kulak Burun Bogaz Ihtis Derg. 2016 Sep-Oct;26(5):283-92
pubmed: 27888826
Cell Death Dis. 2018 Feb 21;9(3):303
pubmed: 29467441
PLoS One. 2014 Jun 30;9(6):e99763
pubmed: 24978478
Nat Rev Cancer. 2013 Feb;13(2):97-110
pubmed: 23344542
Liver Int. 2012 Aug;32(7):1064-78
pubmed: 22583549
Oncotarget. 2018 Feb 14;9(18):14642-14651
pubmed: 29581870
Nature. 2015 Nov 26;527(7579):472-6
pubmed: 26560033
Curr Opin Cell Biol. 2016 Dec;43:7-13
pubmed: 27371787
Sci Rep. 2017 Sep 7;7(1):10832
pubmed: 28883453
Oncotarget. 2014 Jun 15;5(11):3880-94
pubmed: 25003810
Oncotarget. 2017 Mar 21;8(12):20380-20393
pubmed: 28099910
Cells. 2019 Sep 20;8(10):
pubmed: 31547193
Eur J Clin Invest. 2016 May;46(5):398-407
pubmed: 26919035
Diagn Pathol. 2013 May 24;8:89
pubmed: 23706092
Oncol Lett. 2017 Mar;13(3):1725-1730
pubmed: 28454316
Chest. 2009 Jul;136(1):260-271
pubmed: 19584208
PLoS One. 2014 Jun 27;9(6):e100413
pubmed: 24971456
Ann Thorac Med. 2017 Jul-Sep;12(3):191-198
pubmed: 28808491
J Exp Clin Cancer Res. 2019 Jan 6;38(1):5
pubmed: 30612578
J Cell Biol. 2011 Sep 19;194(6):825-39
pubmed: 21930775
Cancer Manag Res. 2018 Jun 08;10:1471-1478
pubmed: 29922091
PLoS One. 2015 Feb 23;10(2):e0117518
pubmed: 25706386
Front Oncol. 2018 Nov 05;8:505
pubmed: 30456206
Tumour Biol. 2013 Oct;34(5):2943-9
pubmed: 23696028
Eur J Clin Invest. 2014 Nov;44(11):1072-94
pubmed: 25257753
Pharmacol Ther. 2018 Feb;182:80-94
pubmed: 28834698
Mol Cancer Ther. 2012 Nov;11(11):2362-72
pubmed: 22933707
Int J Mol Sci. 2019 Aug 25;20(17):
pubmed: 31450715
J Thorac Oncol. 2015 Sep;10(9):1240-1242
pubmed: 26291007
Tumour Biol. 2015 Nov;36(11):9073-81
pubmed: 26084613
Oncogene. 2012 Feb 23;31(8):1045-54
pubmed: 21743493
Genes Dev. 2009 Nov 15;23(22):2625-38
pubmed: 19933152
Br J Cancer. 2017 Sep 26;117(7):974-983
pubmed: 28850563
Mol Oncol. 2017 Jul;11(7):718-738
pubmed: 28590039
Semin Cancer Biol. 2014 Aug;27:39-45
pubmed: 24954011
Int J Clin Exp Med. 2014 Nov 15;7(11):4352-6
pubmed: 25550954
Transl Lung Cancer Res. 2015 Jun;4(3):236-41
pubmed: 26207211
Thorac Cardiovasc Surg. 2000 Oct;48(5):294-9
pubmed: 11100763
Transl Lung Cancer Res. 2016 Jun;5(3):288-300
pubmed: 27413711
Cancer Microenviron. 2017 Dec;10(1-3):87-94
pubmed: 29098659